These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28277345)

  • 1. A Treat-to-Target Strategy Preserves Work Capacity in a Rheumatoid Arthritis Inception Cohort Treated With Combination Conventional DMARD Therapy.
    Wechalekar MD; Quinn S; Lester S; Metcalf RG; Shanahan E; Walker JG; Smith MD; Hill CL; Shanahan EM; Proudman SM
    J Clin Rheumatol; 2017 Apr; 23(3):131-137. PubMed ID: 28277345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.
    Halpern MT; Cifaldi MA; Kvien TK
    Ann Rheum Dis; 2009 Jun; 68(6):930-7. PubMed ID: 18829616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
    Vázquez I; Graell E; Gratacós J; Cañete JD; Viñas O; Ercilla MG; Gómez A; Hernández MV; Rodríguez-Cros JR; Larrosa M; Sanmartí R
    Clin Exp Rheumatol; 2007; 25(2):231-8. PubMed ID: 17543147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with rheumatoid arthritis: cross-sectional study of a single-center real-world inception cohort.
    Ling E; Ofer-Shiber S; Goren O; Molad Y
    Isr Med Assoc J; 2013 Dec; 15(12):758-62. PubMed ID: 24449980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Hakala M; Järvinen P; Ahonen J; Forsberg S; Leirisalo-Repo M;
    Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treat-to-target approach in daily clinical practice in Pakistani patients with early Rheumatoid Arthritis.
    Farman S; Ahmad NM; Saeed MA; Asad K; Shabbir G
    J Coll Physicians Surg Pak; 2015 Feb; 25(2):129-33. PubMed ID: 25703758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up.
    Graell E; Vazquez I; Larrosa M; Rodríguez-Cros JR; Hernández MV; Gratacós J; Gómez A; Cañete JD; Gómez-Puerta JA; Sanmartí R
    Clin Exp Rheumatol; 2009; 27(2):284-91. PubMed ID: 19473570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
    Proudman SM; James MJ; Spargo LD; Metcalf RG; Sullivan TR; Rischmueller M; Flabouris K; Wechalekar MD; Lee AT; Cleland LG
    Ann Rheum Dis; 2015 Jan; 74(1):89-95. PubMed ID: 24081439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study.
    Brenol CV; da Chakr RM; Andrade NP; Toni M; Laurindo IM; Brenol JC; Xavier RM
    Clin Rheumatol; 2015 Oct; 34(10):1781-5. PubMed ID: 25771853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS).
    Young A; Dixey J; Kulinskaya E; Cox N; Davies P; Devlin J; Emery P; Gough A; James D; Prouse P; Williams P; Winfield J
    Ann Rheum Dis; 2002 Apr; 61(4):335-40. PubMed ID: 11874837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study.
    Verschueren P; Esselens G; Westhovens R
    Scand J Rheumatol; 2009; 38(3):166-72. PubMed ID: 19169906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.